Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)
Eric Hedrick(Florida Hospital Cancer Institute), Axel Grothey(Campbell Clinic), Suprith Badarinath(Abbott Northwestern Hospital), Sayo Suzuki(Abbott Northwestern Hospital), John D. Hainsworth(Sarah Cannon), Wei Dong(Abbott Northwestern Hospital), Mary M. Sugrue(Ingalls Memorial Hospital), Patrick J. Flynn(American Society of Clinical Oncology), Allen Lee Cohn(Rocky Mountain Cancer Centers), Mark Kozloff(Ingalls Memorial Hospital)
Cited by 87
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
|New England Journal of Medicine|2018|1.1k